Y-mAbs Therapeutics Appoints New CFO, Shares Dip -2.1%

Y-mabs Therapeutics, Inc. has recently appointed Peter Pfreundschuh as its new Chief Financial Officer, effective June 28, 2024. The company's President and CEO, Mike Rossi, expressed confidence in the appointment, citing the critical point Y-mabs is at as it gains commercial traction with Danyelza® and advances the development of its SADA-PRIT technology platform.

Mr. Pfreundschuh brings a wealth of experience from the healthcare sector, having previously served as CFO at Voyager Therapeutics, Inc., Frequency Therapeutics, Inc., and Urogen Pharma Ltd., among others. Notably, he currently serves on the board of directors of Northstar Medical Technologies, LLC.

Y-mabs is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic cancer products. Its product pipeline includes Danyelza® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

This appointment comes at a crucial time for the company, with Mr. Pfreundschuh expressing excitement to join Y-mabs during this pivotal period. He emphasized the solid financial foundation fueled by the growing commercial success of Danyelza® on a global scale and expressed his belief in Y-mabs' potential to advance the SADA-PRIT technology platform and change the way radiopharmaceutical therapies are used to improve patient lives.

As Mr. Pfreundschuh takes on his new role, he will be based in Y-mabs' New York and New Jersey offices, further solidifying the company's presence in the U.S. market. As a result of these announcements, the company's shares have moved -2.1% on the market, and are now trading at a price of $11.83. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.